These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15505021)

  • 21. Rotational atherectomy with drug-eluting stents: a necessary technique in the current era.
    Lozano I; Rondan J; Avanzas P
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):160; author reply 161. PubMed ID: 21069801
    [No Abstract]   [Full Text] [Related]  

  • 22. [Initial result of Gianturco-Roubin coronary stent].
    Tateyama H; Katoh O; Kobayashi T; Shibata N
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):954-60. PubMed ID: 12436644
    [No Abstract]   [Full Text] [Related]  

  • 23. The forgotten player of in-stent restenosis: endothelial dysfunction.
    Celik T; Iyisoy A; Kursaklioglu H; Celik M
    Int J Cardiol; 2008 Jun; 126(3):443-4. PubMed ID: 17466392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronary restenosis: a new strategy for the future?
    Pelliccia F; Pasceri V
    Lancet; 2007 Aug; 370(9587):541-2. PubMed ID: 17707731
    [No Abstract]   [Full Text] [Related]  

  • 25. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy.
    Wykrzykowska JJ; Onuma Y; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F7-8. PubMed ID: 22100680
    [No Abstract]   [Full Text] [Related]  

  • 26. Gender medicine and drug eluting coronary stents.
    Kornowski R
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):814-6. PubMed ID: 21104730
    [No Abstract]   [Full Text] [Related]  

  • 27. Treating the left main bifurcation lesion: the "three stent solution".
    Uretsky BF
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):42-3. PubMed ID: 19089935
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug-eluting stents: safe but not sufficient.
    Vogel RA
    JACC Cardiovasc Interv; 2009 Jun; 2(6):513-4. PubMed ID: 19539254
    [No Abstract]   [Full Text] [Related]  

  • 29. Coronary angioscopy and optical coherence tomography for confirmation of drug-coated neointimal plaque after paclitaxel-coated balloon angioplasty for in-stent restenosis.
    Yoneyama K; Koyama K; Tanabe Y; Mitarai T; Kamijima R; Kuwata S; Yamazaki H; Nakano E; Kongoji K; Harada T; Akashi YJ
    Int J Cardiol; 2014 Oct; 176(3):1207-9. PubMed ID: 25129263
    [No Abstract]   [Full Text] [Related]  

  • 30. Pioglitazone to reduce restenosis after bare-metal stent placement?
    Nissen SE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):532-3. PubMed ID: 19539257
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral sirolimus after bare metal stent implantation: a glimpse to the future.
    Mieres J
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):158-9. PubMed ID: 20931667
    [No Abstract]   [Full Text] [Related]  

  • 32. [Assessment of coronary artery stents in computed tomography: state of the art].
    Krupiński M; Miszalski-Jamka T; Klimeczek P; Banyś RP; Irzyk M; Laskowicz B; Pasowicz M
    Przegl Lek; 2010; 67(2):123-6. PubMed ID: 20557013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A critical appraisal of the Janus carbostent.
    Kornowski R
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):249-50. PubMed ID: 19156897
    [No Abstract]   [Full Text] [Related]  

  • 35. Dexamethasone-eluting vascular stents.
    Hämäläinen M; Nieminen R; Uurto I; Salenius JP; Kellomäki M; Mikkonen J; Kotsar A; Isotalo T; Teuvo Tammela LJ; Talja M; Moilanen E
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):296-301. PubMed ID: 23374962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
    Bhatt DL; Chew DP; Grines C; Mukherjee D; Leesar M; Gilchrist IC; Corbelli JC; Blankenship JC; Eres A; Steinhubl S; Tan WA; Resar JR; AlMahameed A; Abdel-Latif A; Tang WH; Brennan D; McErlean E; Hazen SL; Topol EJ
    Am Heart J; 2007 Jul; 154(1):137-43. PubMed ID: 17584566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular smooth muscle cell proliferation in restenosis.
    Marx SO; Totary-Jain H; Marks AR
    Circ Cardiovasc Interv; 2011 Feb; 4(1):104-11. PubMed ID: 21325199
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug eluting stents in CTOs: why not?
    Vetrovec GW
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):333-4. PubMed ID: 21328678
    [No Abstract]   [Full Text] [Related]  

  • 39. Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?
    Park SW; Hong MK; Oh SJ; Moon DH
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1219-23. PubMed ID: 15205921
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-eluting stent endothelium: presence or dysfunction.
    van Beusekom HM; Serruys PW
    JACC Cardiovasc Interv; 2010 Jan; 3(1):76-7. PubMed ID: 20129573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.